Your fact-checks will appear here
Disease-targeted anti-amyloid immunotherapies for early-stage Alzheimer's
No reliable information about a therapy called "memo blast" is present in the supplied reporting, so its effects cannot be judged from these sources; the documents instead evaluate anti-amyloid monocl...
Current scientific reporting finds consistent preclinical evidence that honey and certain honey-derived compounds can influence biological pathways implicated in Alzheimer’s disease—oxidative stress, ...
Following an unproven Alzheimer’s treatment carries immediate medical risks, regulatory uncertainty, and financial and social harms that can outweigh hoped-for benefits; recent controversies around an...
The FDA currently recognizes two classes of Alzheimer’s treatments: disease-targeted, anti-amyloid immunotherapies that have been shown to reduce brain amyloid and modestly slow cognitive decline in e...